“My cancer was missed… I’m passionate it doesn’t happen again.”
Latest articles: MGUS is a benign condition which does not usually require treatment. However, a small number of patients diagnosed with MGUS will go on to develop myeloma. Understanding MGUS Monoclonal gammopathy of undetermined significance (MGUS) is a benign...read more
Latest articles: With communication at the heart of GatewayC and fundamental to improving patient care, this blog series focuses on introductions and reflections from the team behind the programme. In this post, we’re introducing Tom, Senior Media Technologist. Could...read more
GatewayC aims to support primary care in the early diagnosis of cancer, to support patient outcomes and experiences.
According to the National Cancer Diagnosis Audit, around one quarter of patients have three or more visits to primary care before a referral is made. For more than one in five patients, GPs in the audit considered there to have been an avoidable delay in the patient receiving their cancer diagnosis.*
“My cancer was missed…”
Saeed was misdiagnosed several times by a number of healthcare professionals over the course of 12 months. He was diagnosed with stage 2 colorectal cancer in 2009.
Following successful treatment, Saeed has used his experience, along with other patient representatives, to contribute to the development of each course on GatewayC. Following the launch of GatewayC’s Colorectal Cancer – Early Diagnosis course, Saeed said:
“When I was involved in the [GatewayC] colorectal course, I could quite clearly see that if this course was available for the doctors at the time that my cancer was diagnosed, it would not have been missed.”
We’re grateful to Saeed and our fantastic user representatives, who continue to share their experiences and contribute to relevant education on GatewayC.
Start your learning today
Log in to GatewayC to choose from our range of online cancer courses and start your learning today.
* Results from the audit cited these as patient (26%), clinician (28%) or system (34%) factors.